138 Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
Regular and Young Investigator Award Abstracts（2022）
摘要
Clinicaltrials.gov, identifier NCT02866383.
更多查看译文
关键词
biomarker,immune checkpoint inhibition,CHI3L1,pancreatic cancer,YKL-40
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要